UNSPSC 51434105: Azamethonium bromide

This classification denotes an antihypertensive agent with the molecular formula C13H33N3.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K6NEI0MSR, chemically known as 3,3,6,9,9-pentamethyl-6-aza-3,9-diazoniaundecan dibromid but more generally known as azamethonium bromide, which bears US NIH Compound Identifier 9382. European Medicines Agency schedules Azamethonium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05632MIG.

UNSPSC 51434105 Azamethonium bromide is a Commodity code that nominally designates a specific pharmaceutical agent, but the actual state and local procurement activity under this code reflects the broader category of emergency medical and multi-source pharmaceutical supply. State and local governments procure generic and branded pharmaceuticals, injectable medications for advanced life support, and over-the-counter products through this code to support fire rescue operations, emergency medical services, state health programs, and cooperative purchasing networks. Issuing bodies include city procurement offices, state health and human services departments, and multistate cooperative purchasing alliances. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent the range of end-users driving demand; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, demonstrates the prevalence of aggregated procurement vehicles in this space.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP contract extending to participating states including Oregon. The City of Tampa's Purchasing Department issued an Invitation for Bid (IFB) in April 2026 (Solicitation 26P00188) for Advanced Life Support Medications—specifically Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the solicitation includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Department of Administration issued an RFP through MMCAP (Solicitation S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring vendors to supply through three authorized wholesalers with contract award effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued an exploratory RFI (No. HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling future formal procurement activity.